Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

The Sarcoma Assessment Measure (SAM): Preliminary Psychometric Validation of a Novel Patient-Reported Outcome Measure

Lee Hulbert-Williams
* ,
Nicholas J. Hulbert-Williams
,
Ana Martins
,
Lesley Storey
,
Jennie Bradley
ORCID logo ,
Hatty O’Sullivan
,
Lorna A. Fern
ORCID logo ,
Maria Lawal
,
Rachael Windsor
,
Craig Gerrand
,
Jeremy S. Whelan
,
Lindsey Bennister
,
Mary Wells
,
Rachel M Taylor
* ORCID logo
Version 1 : Received: 28 November 2023 / Approved: 28 November 2023 / Online: 29 November 2023 (09:51:25 CET)

A peer-reviewed article of this Preprint also exists.

Hulbert-Williams, L.; Hulbert-Williams, N.J.; Martins, A.; Storey, L.; Bradley, J.; O’Sullivan, H.; Fern, L.A.; Lawal, M.; Windsor, R.; Gerrand, C.; Whelan, J.S.; Bennister, L.; Wells, M.; Taylor, R.M. The Sarcoma Assessment Measure (SAM): Preliminary Psychometric Validation of a Novel Patient-Reported Outcome Measure. Cancers 2024, 16, 1096. Hulbert-Williams, L.; Hulbert-Williams, N.J.; Martins, A.; Storey, L.; Bradley, J.; O’Sullivan, H.; Fern, L.A.; Lawal, M.; Windsor, R.; Gerrand, C.; Whelan, J.S.; Bennister, L.; Wells, M.; Taylor, R.M. The Sarcoma Assessment Measure (SAM): Preliminary Psychometric Validation of a Novel Patient-Reported Outcome Measure. Cancers 2024, 16, 1096.

Abstract

The Sarcoma Assessment Measure (SAM) was developed as a sarcoma-specific patient-reported outcome measure to be used in clinical practice. We have reported in detail how SAM has been developed in collaboration with patients and healthcare professionals. The aim of this paper is to report the preliminary validation of SAM. The 22-item SAM was administered alongside a validated quality of life questionnaire and measure of activities of daily living. Linear modelling was used to build a measure, which had predictive validity in comparison to more established outcome measures. Of the 762 patients who participated in the study, 44.1% identified as male, and participant age ranged from 13-82 years. Clinically, participants presented with a range of soft tissue (82.2%) and bone (21.8%) sarcomas. Our preliminary analysis indicates that SAM accounts for 35% of the Global quality of life scale and 18% of the TESS so psychometrically it overlaps with quality of life and activities of daily living, but also measures distinct concerns. This demonstrates that this measure picks up issues that are important to patients with sarcoma that are not reflected in other measures. We have established the preliminary validity of SAM and believe it has utility as a patient-reported outcome measure both as a research tool and for assessing the impact of symptoms and dysfunction related to sarcoma as part of clinical care. Further validation using a larger and more clinically diverse sample is now needed.

Keywords

soft tissue sarcoma; bone tumours; gastrointestinal stromal tumours; quality of life; patient-reported outcome

Subject

Public Health and Healthcare, Other

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.